Curie Capital
Curie Capital is a life science-focused venture capital firm established in 2018 and headquartered in Amsterdam, Netherlands. The firm aims to invest in early-stage companies within the biotechnology, pharmaceutical, and medical technology sectors, with particular emphasis on therapeutics, diagnostics, and medical devices. Founded by Mariette van der Velden and Han de Groot, both of whom possess extensive experience in investing and entrepreneurship, Curie Capital combines their complementary skills and networks to support the development of talented teams and innovative science and technology. The firm seeks to foster the growth of its portfolio companies from inception through to potential public exit.
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.
Cleara Biotech
Seed Round in 2022
Cleara Biotech B.V., based in Utrecht, the Netherlands, focuses on developing therapeutics aimed at selectively eliminating senescent and senescent-like cancer cells. The company is particularly engaged in creating FOXO4-based anti-senescence drugs designed to counteract chemotoxicity and address therapy-resistant cancer cells. By targeting these problematic cells, Cleara Biotech seeks to advance cancer treatment and improve patient outcomes.
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.